What is Anoro Ellipta 55/22 mcg

Anoro Ellipta 55/22 mcg is a combination bronchodilator inhaler used to manage Chronic Obstructive Pulmonary Disease (COPD), including chronic Bronchitis and Emphysema. It contains two active salts, Umeclidinium (55 mcg) and Vilanterol (22 mcg). Umeclidinium belongs to the Long-Acting Muscarinic Antagonist (LAMA) class, while Vilanterol belongs to the Long-Acting Beta-2 Agonist (LABA) class.

Together, these two salts relax and open the airways in the lungs. Umeclidinium blocks muscarinic receptors to reduce airway constriction, while Vilanterol stimulates beta-2 receptors to widen the bronchial passages. This dual action improves airflow, reduces breathlessness, and supports easier breathing throughout the day.

Anoro Ellipta 55/22 mcg is manufactured by GlaxoSmithKline (GSK), a globally recognized pharmaceutical company. GSK produces this inhaler in a Good Manufacturing Practice (GMP)-compliant facility. The active salts, Umeclidinium and Vilanterol, are both Food and Drug Administration (FDA)-approved, and this medication is also WHO-approved, ensuring high standards of quality and safety.

The inhaler is approved for once-daily use in adults with COPD. It is not intended for the treatment of Asthma or for relieving sudden breathing attacks. If a dose is missed, the next dose should be taken at the regular time without doubling. Overuse of the inhaler can increase the risk of side effects, especially heart-related effects.

Common Anoro Ellipta 55/22 mcg side effects include sore throat, sinus infection, constipation, diarrhea, and muscle spasms. Seek medical advice if symptoms worsen, breathing suddenly worsens, or signs of allergy, eye pain, or urinary trouble appear.

Store the inhaler at room temperature, between 68°F and 77°F (20°C and 25°C). Keep it in the sealed tray until use, away from moisture and direct sunlight. Always consult a doctor before starting or modifying this medication.

What are the benefits of taking Anoro Ellipta 55/22 mcg

The Chronic Obstructive Pulmonary Disease medication combines Umeclidinium (LAMA) and Vilanterol (LABA) to target two different airway pathways, delivering broader relief than a single bronchodilator:

• Easier breathing: Opens narrowed airways to improve airflow and reduce breathlessness during daily activities.
• COPD flare-up reduction: Regular use helps lower the frequency and severity of COPD episodes.
• Once-daily dosing: A single inhalation provides full 24-hour airway support, keeping the routine simple.

How to take Anoro Ellipta 55/22 mcg

The long-acting bronchodilator for COPD is a prescription maintenance inhaler that should be used only as directed by a doctor. Here are general guidelines for using this medication:

• Take one inhalation once daily, at the same time each morning or evening.
• Inhale the dose through the mouthpiece.
• Breathe out fully before inhaling, then breathe in steadily and deeply through the mouthpiece.
• This inhaler can be used with or without food.
• Do not take more than one dose in 24 hours.

Strengths and Substitutes

Anoro Ellipta is also available in the following strengths on Cheap Medicine Shop. In addition, there are a few other inhaler options for respiratory support that can be considered relevant alternatives, depending on the doctor’s advice.

View all substitutes

What are the side effects of Anoro Ellipta 55/22 mcg

Like many inhaled COPD medicines, mild side effects often improve as the body adjusts. Consult a healthcare professional if they persist, become bothersome, or worsen:

• Nasopharyngitis (runny or stuffy nose)
• Sore throat
• Sinus infection
• Constipation
• Diarrhea

Safety Advice

Liver Disease

The dry powder inhaler for COPD is generally used with caution in liver problems. No dose adjustment of the combination bronchodilator inhaler is necessary in mild to moderate hepatic impairment, but severe hepatic damage has not been adequately studied. A doctor should review ongoing treatment before use.

Kidney Impairment

Anoro Ellipta 55/22 mcg is generally considered suitable for individuals with kidney impairment. Typically, no dose adjustment is required, even in severe renal impairment. However, a doctor should always review the full medical history before starting or continuing use.

Pregnant and Breastfeeding women

Human data during pregnancy are insufficient to establish safety, and no information is available on whether the active ingredients pass into human milk or affect a breastfed child. A doctor should carefully weigh the benefit of the medication to the individual against any potential risk before continuing use during pregnancy or breastfeeding.

Avoid

LAMA LABA dual bronchodilator therapy is not suitable for individuals with Asthma or a severe allergy to milk proteins or any ingredient in the formulation. It should not be taken alongside other medicines that contain a LABA or an anticholinergic. Caution is advised when using it with strong CYP3A4 inhibitors, as this may raise the risk of cardiovascular effects. People with Narrow-angle Glaucoma or urinary retention should inform their doctor before use.